List of Figures
Figure 1: Antibacterial Therapeutics, US, Innovation Trends in Product Approvals, 1987–2014 6
Figure 2: Antibacterial Therapeutics. US. Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006–2013 8
Figure 3 : Antibacterial Therapeutics, Global, Molecule Types and Molecular Targets of Marketed Products, 2017 20
Figure 4: Antibacterial Therapeutics, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area 2017 21
Figure 5:Antibacterial Therapeutics, Global, Pipeline Products by Stage of Development and Molecule Type, 2017 22
Figure 6: Tuberculosis, Pneumonia, MRSA, and Sepsis, Global, Pipelines by Stage of Development, 2017 23
Figure 7: Tuberculosis, Pneumonia, MRSA, and Sepsis, Global, Pipelines by Molecule Type, 2017 24
Figure 8: Antibacterial Therapeutics, Global, Pipeline by Molecular Target, 2017 25
Figure 9: Tuberculosis, Pneumonia, MRSA, Sepsis, Global, Pipelines by Molecular Target, 2017 26
Figure 10: Molecular Target Category Comparison, Pipeline and Marketed Products, 2017 27
Figure 11: Antibacterial Therapeutics, Global, Pipeline by Molecular Target Class, First-in-Class Status and Stage of Development, 2017 28
Figure 12: Antibacterial Therapeutics Market, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Stage of Development (%), 2017 28
Figure 13: Antibacterial Therapeutics Market, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Molecule Type (%), 2017 29
Figure 14: Antibacterial Therapeutics Market, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Molecular Target (%), 2017 29
Figure 15: Antibacterial Therapeutics Market, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target, 2017 30
Figure 16: Antibacterial Therapeutics, Global, First-in-Class Products in Pipeline (Part 1), 2017 31
Figure 17: Antibacterial Therapeutics, Global, First-in-Class Products in Pipeline (Part 2), 2017 32
Figure 18: Antibacterial Therapeutics, Global, First-in-Class Products in Pipeline (Part 3), 2017 33
Figure 19: Antibacterial Therapeutics, Global, First-in-Class Products in Pipeline (Part 4), 2017 33
Figure 20: Antibacterial Therapeutics, Global, First-in-Class Products in Pipeline (Part 5), 2017 34
Figure 21: Antibacterial Therapeutics, Global, First-in-Class Products in Pipeline (Part 6), 2017 34
Figure 22: Antibacterial Therapeutics, Global, First-in-Class Products in Pipeline (Part 7), 2017 35
Figure 23: Antibacterial Therapeutics, Global, First-in-class Human Targets, 2017 37
Figure 24: Sepsis, Global, First-in-class Targets, 2017 37
Figure 25: MRSA, Global, First-in-class Targets, 2017 38
Figure 26: Pneumonia, Global, First-in-class Targets, 2017 38
Figure 27: Tuberculosis, Global, First-in-class targets, 2017 39
Figure 28: Antibacterial Therapeutics, Global, Licensing Deals by Stage of Development, 2006–2015 51
Figure 29 :Pharmaceutical Industry, Global, Industry-Wide Licensing Deals by Deal Value, Upfront Payment Value, Stage of 52
Figure 30: Antibacterial Therapeutics, Global, Licensing Deals by Region and Value, 2006–2017 53
Figure 31: Antibacterial Therapeutics, Global, Licensing Deals by Stage and Value, 2006–2017 54
Figure 32: Antibacterial Therapeutics, Global, Licensing Deals by Molecular Target, 2006–2017 55
Figure 33: Antibacterial Therapeutics, Licensing Deals with Disclosed Values, 2006–2017, Part 1 56
Figure 34: Antibacterial Therapeutics, Licensing Deals with Disclosed Values, 2006–2017, Part 2 56
Figure 35: Antibacterial Therapeutics, Licensing Deals with Disclosed Values, 2006–2017, Part 3 57
Figure 36: Antibacterial Therapeutics, Global, Co-development Deals by Region and Value, 2006–2017 58
Figure 37: Antibacterial Therapeutics, Global, Co-development Deals by Stage and Value, 2006–2017 59
Figure 38: Antibacterial Therapeutics, Global, Co-development Deals by Molecule Type, 2006–2017 60
Figure 39: Antibacterial Therapeutics, Global, Co-development Deals with Disclosed Values, 2006–2017 61
Figure 40: Antibacterial Therapeutics, Global, First-in-class Programs in Active Development Without Recorded Prior Deal Involvement, 2017 (Part 1) 62
Figure 41 :Antibacterial Therapeutics, Global, First-in-class Programs in Active Development Without Recorded Prior Deal Involvement, 2017 (Part 2) 63
Figure 42: Antibacterial Therapeutics, Global, First-in-class Programs in Active Development Without Recorded Prior Deal Involvement, 2017 (Part 3) 64
Figure 43: Antibacterial Therapeutics, Global, First-in-class Programs in Active Development Without Recorded Prior Deal Involvement, 2017 (Part 4) 65
Figure 44: Antibacterial Therapeutics, Global, First-in-class Programs in Active Development With Recorded Prior Deal Involvement, 2017 66
Figure 45: Antibacterial Therapeutics, Global, Products in Pipeline (Part 1), 2017 67
Figure 46: Antibacterial Therapeutics, Global, Products in Pipeline (Part 2), 2017 68
Figure 47: Antibacterial Therapeutics, Global, Products in Pipeline (Part 3), 2017 69
Figure 48: Antibacterial Therapeutics, Global, Products in Pipeline (Part 4), 2017 70
Figure 49: Antibacterial Therapeutics, Global, Products in Pipeline (Part 5), 2017 71
Figure 50: Antibacterial Therapeutics, Global, Products in Pipeline (Part 6), 2017 72
Figure 51: Antibacterial Therapeutics, Global, Products in Pipeline (Part 7), 2017 73
Figure 52: Antibacterial Therapeutics, Global, Products in Pipeline (Part 8), 2017 74
Figure 53: Antibacterial Therapeutics, Global, Products in Pipeline (Part 9), 2017 75
Figure 54: Antibacterial Therapeutics, Global, Products in Pipeline (Part 10), 2017 76
Figure 55: Antibacterial Therapeutics, Global, Products in Pipeline (Part 11), 2017 77
Figure 56: Antibacterial Therapeutics, Global, Products in Pipeline (Part 12), 2017 78
Figure 57: Antibacterial Therapeutics, Global, Products in Pipeline (Part 13), 2017 79
Figure 58: Antibacterial Therapeutics, Global, Products in Pipeline (Part 14), 2017 80
Figure 59: Antibacterial Therapeutics, Global, Products in Pipeline (Part 15), 2017 81
Figure 60: Antibacterial Therapeutics, Global, Products in Pipeline (Part 16), 2017 82
Figure 61: Antibacterial Therapeutics, Global, Products in Pipeline (Part 17), 2017 83
Figure 62: Antibacterial Therapeutics, Global, Products in Pipeline (Part 18), 2017 84
Figure 63: Antibacterial Therapeutics, Global, Products in Pipeline (Part 19), 2017 85
Figure 64: Antibacterial Therapeutics, Global, Products in Pipeline (Part 20), 2017 86
Figure 65: Antibacterial Therapeutics, Global, Products in Pipeline (Part 21), 2017 87
Figure 66: Antibacterial Therapeutics, Global, Products in Pipeline (Part 22), 2017 88
Figure 67: Antibacterial Therapeutics, Global, Products in Pipeline (Part 23), 2017 89
Figure 68: Antibacterial Therapeutics, Global, Products in Pipeline (Part 24), 2017 90
Figure 69: Antibacterial Therapeutics, Global, Products in Pipeline (Part 25), 2017 91
Figure 70: Antibacterial Therapeutics, Global, Products in Pipeline (Part 26), 2017 92
Figure 71: Antibacterial Therapeutics, Global, Products in Pipeline (Part 27), 2017 93
Figure 72: Antibacterial Therapeutics, Global, Products in Pipeline (Part 28), 2017 94
Figure 73: Antibacterial Therapeutics, Global, Products in Pipeline (Part 29), 2017 95